anti-interleukin-6 living meta-analysis of clinical studies

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study

	COVID 19 all comers	COVID-19 mild to moderate

	COVID 19 hospitalized	COVID 19 all comers	COVID-19 mild to moderate
anti-interleukin-6
sarilumab	CORIMUNO-SARI-1 ...
sarilumab high dose (400mg)		sarilumab phase 2 high dose
sarilumab low dose (200mg)		sarimulab phase 2 low dose
tocilizumab	EMPACTA Declercq J ... Tsai NCT04577534 ... RCT-TCZ-COVID-19 SAM-COVID-19 EU-CTR2020-001375-32 ... EU-CTR2020-001748-24 ... Martinez-Sanz RECOVERY NCT04479358 ... HNF Hospital Tocilizumab multidisciplinary team Soin AS ... NCT04434717 ... Rutgers Dongsheng Wang Colaneri NCT04412772 ...	TOCOVID BACC Bay Tocilizumab Trial	Capra